As it has become somewhat of a tradition, the Katfriends at Kisaco Research wish to inform IPKat Readers that their Life Sciences Strategy Summit on IP & Exclusivity returns to Munich this October (13–15 October 2025, Infinity Hotel) and promises to be bigger, broader, and more commercially relevant than ever before.

Against a backdrop of shifting case law, evolving EU regulations, and the rise of the UPC, this year’s summit is a key place where originators, generics, biosimilars, biotech, regulators, and law firms come together to shape the future of IP strategy in Europe.

This year’s agenda features the following speakers:

In-House Counsel Highlights:

• James Horgan, Chief IP Counsel – Policy & Litigation, MSD

• Julia Pike, Global Head of IP, Sandoz

• Ana Gabarda, Director – Corporate Patent Counsel, Merck

• Toni Santamaria, SVP Intellectual Property & Legal, Adalvo

• Maurizio di Stasio, Senior Patent Counsel, Bayer

• Mathilde Rauline, Head of Greater Europe Patent Litigation, Sanofi

• Fleur Herrenschmidt, Chief Legal Officer, Norgine

• Natalia Wright, Associate General Patent Counsel, UCB

• Plus many more from Novartis, Amgen, BioNTech, Fresenius Kabi, Chiesi, Polpharma, Regeneron, and others

Judicial & Patent Office Faculty:

• Martin Schmidt, Technically Qualified Judge, UPC

• Roberto Romandini, Legal Member, Boards of Appeal, EPO

• Oliver Werner, Head of SPC Working Group, German PTO

• Patrick Purcell, Senior Patent Examiner, UK IPO

• Fergal Brady, Patent Examiner, Irish IPO

• Damien Filippini, Patent Engineer, INPI

• And more, providing direct insights into case law and procedural shifts

With over 50 senior in-house counsel, patent office examiners, and UPC judges, participants will gain a 360° view of the legal, regulatory, and competitive challenges driving exclusivity decisions across the life sciences sector.

New to the 2025 edition are the following topics:

• Unitary SPC developments: What a centralized SPC system means for exclusivity strategy.

• Patent quality across EPO & PTAB: Tackling unpredictability and enforcement challenges.

• AI in Life Sciences IP: Regulatory changes, FTO implications, and future-proofing strategy.

• Divisional patents in EU & US: Impact of Teva cases and FTC decisions.

• Bolar exemptions & safe harbor: Cross-jurisdictional differences shaping trial strategies.

• Second medical use & skinny labels: Navigating complex enforcement landscapes.

• Regulatory exclusivity reforms: New EU legislation, Tecfidera implications, and portfolio management.

• Antibody exclusivity: EPO vs USPTO comparisons, inventive step debates, and Amgen/Sanofi impact.

Source: https://ipkitten.blogspot.com/2025/09/life-sciences-strategy-summit-on-ip.html